RISE data show UZEDY to be an effective long-acting injectable (LAI) antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of risperidone1In the RISE study, UZEDY significantly prolonged time to impending relapse by up to 5.0 times (once-monthly.
Press Release Stockholm, Sweden, November 2, 2023 Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data Three abstracts.
MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week results, in which the primary endpoint was met with 29 percentage points delta versus placebo at week 12. The data showed that the maintenance treatment with its Nanobody sonelokimab led to further improvements in HiSCR75 response rates and other clinically relevant outcomes. The 24-week results show th
Before closing out their discussion on first-line management of follicular lymphoma, experts consider the importance of patient monitoring and discuss the diminished role of maintenance therapy.